CVS Health ’s CVS Pharmacy and Consumer Wellness (“PCW”) segment has seen steady growth in recent months, with revenues up 11.1% year over year in the first quarter of 2025.

Barclays upgraded CVS Health Inc (NYSE:CVS) on higher Pharmacy & Consumer Wellness (PCW) estimates as headwinds are offset by share gains, with further upside potential from CostVantage. Despite ...

CVS' Pharmacy & Consumer Wellness segment added $32.4B in revenue with ~12% YoY growth as prescriptions filled on a 30-day equivalent basis increased by ~6%, mainly due to higher utilization.

On Wednesday, CVS Health Corp (NYSE:CVS) reported fourth-quarter sales of $97.71 billion, beating the consensus of $97.19 billion. Total revenues increased 4.2%, driven by growth in the Health ...

In the latest market close, CVS Health (CVS) reached $58.40, with a -0.03% movement compared to the previous day. The stock trailed the S&P 500, which registered a daily gain of 1.7%. Meanwhile ...

CVS Health ’s CVS Pharmacy and Consumer Wellness (“PCW”) segment has seen steady growth in recent months, with revenues up 11.1% year over year in the first quarter of 2025. Performance was supported ...

CVS Health reported Q4 revenue of $97.71B, surpassing the $97.19B consensus. 2025 revenue is expected to exceed $134B, driven by higher prescription volumes. Historic Summer Setup: 3 "Power ...

Barclays upgrades CVS Health to Overweight, citing gains in pharmacy market share and potential upside from CostVantage. CVS is expected to recover 200 basis points in Medicare margins by 2026 ...